Cordance Medical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cordance Medical - overview
Established
2018
Location
Mountain View, CA, US
Primary Industry
Medical Devices & Equipment
About
Cordance Medical is a US-based company specializing in innovative medical devices aimed at enhancing treatment options for brain diseases by non-invasively accessing the brain's therapeutic environment. Cordance Medical was founded in 2018 in Mountain View, US, focusing on developing medical devices that can open the blood-brain barrier (BBB). The company has undergone strategic pivots to refine its technology and approach to market. The latest funding round was a Seed round in October 2025, raising USD 8.
000 mn led by Sonder Capital, with multiple other investors participating. The total amount raised to date is USD 8. 000 mn, with one recorded deal in its history. Cordance Medical's core product is the NeuroAccess™ medical device, which non-invasively and reversibly opens the blood-brain barrier at targeted brain sites.
The device utilizes low-frequency focused ultrasound and microbubbles for precise delivery of therapeutic agents and biomarker measurement, targeting diseases such as brain cancer, Alzheimer's, Parkinson's, and epilepsy. The NeuroAccess™ device is designed for outpatient use across North America and Europe, aiming to improve diagnostic and therapeutic outcomes for patients. Cordance Medical generates revenue through partnerships with healthcare providers, pharmaceutical firms, and research institutions focused on marketing the NeuroAccess™ medical device. Revenue is anticipated from direct sales to healthcare facilities and potential subscription models for ongoing support and maintenance.
The innovative nature of the device supports a pricing strategy reflecting its value to patient care. In October 2025, Cordance Medical raised USD 8. 000 mn in Seed funding, with plans to utilize this capital to advance its first-in-human clinical trial. The company aims to expand into new markets in North America and Europe, enhancing its presence in the healthcare sector as it rolls out its NeuroAccess™ technology.
Future initiatives will focus on product development and market penetration, aligning with the company's long-term growth strategy.
Current Investors
Shanda Capital, SmartGateVC, Sonder Capital
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Medical Equipment Distributors
Website
www.cordancemedical.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.